SQ-LIP-000002 · v1.1 (archived) · View current version →
How common is lipedema, and who does it affect?
Based on currently indexed evidence, lipedema affects predominantly women, with occurrence in men rare but documented (supported by a case series of 5 men and consensus endorsement). The condition almost exclusively presents in females across all clinical cohorts reviewed (U.S., German, Swiss, Italian, and Brazilian samples), with symptom onset most commonly linked to reproductive milestones — puberty (reported in ~48–62% of patients across cohorts) and pregnancy (~41%). A Brazilian screening-based cross-sectional study estimated probable lipedema prevalence at approximately 12.3% of adult women, but this figure relies on self-reported questionnaires without clinical confirmation and carries a low evidence grade; it is likely an overestimate of clinically diagnosed disease and was endorsed with the lowest agreement in a 2025 consensus. True population prevalence and incidence remain poorly defined in the literature. Clinical cohort data consistently describe a condition of middle adulthood (mean ages 38–49 years across studies), with first manifestation typically in adolescence (mean age ~16 years in one German cohort) and a prolonged diagnostic delay averaging ~15 years. Family history is reported by approximately 50% of patients (Swiss cohort, n=381), suggesting a heritable component with undetermined genetic background. The condition is neither rare nor trivial: it carries substantial comorbidity burden including hypothyroidism, depression, chronic venous disease, and reduced quality of life across multiple independent cohorts.
Knowledge freshness = share of the 10 indexed evidence sources from the last 5 years (newest 2025, oldest 2019) . Low freshness flags an ageing evidence base — not that the answer is wrong.
Evidence over time
supporting contradicting refining / context Each dot is a study, placed by year and coloured by whether the linked claim supports or contradicts the answer. As the surveillance loop runs, claim revisions and new evidence will extend this timeline.
Choose a format (Vancouver default). Citing a version captures the evidence state on that date; this page shows the current version — see version history.
What changed in this version
This update substantially expanded the epidemiological and demographic profile of lipedema by adding seven new context claims from large clinical cohorts (U.S., German, Swiss, Italian) and a scoping review, providing consistent data on age of onset, diagnostic delay, family history, reproductive milestone triggers, comorbidity burden, and quality of life impairment — none of which were present in the prior answer.
Supporting claims
- SCR-LIP-000012 supporting
The estimated prevalence of probable lipedema among adult Brazilian women is approximately 12.3%, indicating a common rather than rare condition.
Prevalência e fatores de risco para lipedema no Brasil — Amato et al. (2022) · Brazilian Consensus Statement on Lipedema using the Delphi methodology — Amato et al. (2025)
Contradictory claims
- None indexed yet.
Refining / context
- SCR-LIP-000014 context
Lipedema occurs in men with the classical phenotype (bilateral, symmetrical, foot-sparing lower-limb fat accumulation, negative Stemmer sign), although it almost exclusively affects women and male occurrence is rare.
Lipedema in Men: A Retrospective Case Series of Five Patients From a Brazilian Referral Center — Amato et al. (2025) · Brazilian Consensus Statement on Lipedema using the Delphi methodology — Amato et al. (2025) - SCR-LIP-000076 context
In a national survey of 707 U.S. women with lipedema, the mean age was 48.6 years and mean BMI was 40.9 kg/m², with symptom onset most commonly at puberty (48.0%) or pregnancy (41.2%), and the condition exclusively affected women in this sample.
National survey of patient symptoms and therapies among 707 women with a lipedema phenotype in the United States — Aday et al. (2024) - SCR-LIP-000077 context
In a survey of 209 German female lipedema patients who underwent liposuction, the average age was 38.5 years, first manifestation occurred at age 16, and diagnosis took a mean of 15 years to achieve, with comorbidities including hypothyroidism (35.9%) and depression (23.0%) at rates exceeding general population prevalence.
New Insights on Lipedema: The Enigmatic Disease of the Peripheral Fat — Bauer et al. (2019) - SCR-LIP-000078 context
Lipedema is a serious disease with undetermined genetic background that affects women, first described as a syndrome in 1940, and is neither a cosmetic problem nor a lifestyle issue, though its true prevalence and incidence remain poorly defined in the literature.
Lipedema Research—Quo Vadis? — Ernst et al. (2022) - SCR-LIP-000079 context
In a retrospective series of 106 lipedema patients who underwent liposuction, the cohort was exclusively female with a median BMI of 31.6 kg/m², and showed elevated prevalence of obesity, hypothyroidism, migraine, and depression compared to non-lipedema populations, while diabetes (5%) and dyslipidemia (7%) prevalence were unexpectedly low.
Disease progression and comorbidities in lipedema patients: A 10‐year retrospective analysis — Ghods et al. (2020) - SCR-LIP-000080 context
In a Swiss referral centre cohort of 381 women with lipedema (mean age 41.9 years), 49.9% reported a family history, 62.2% reported symptom onset during adolescence, and 92.1% had comorbidities, with pain affecting 87.9% and significantly reduced quality of life in the majority.
Clinical characteristics, comorbidities, and correlation with advanced lipedema stages: A retrospective study from a Swiss referral centre — Luta et al. (2025) - SCR-LIP-000081 context
In a cohort of 360 Italian women with lipedema of the lower limbs (stages 1–3), the condition was found exclusively in women and was associated with comorbidities including vitamin D insufficiency, chronic venous disease, dyslipidemia, depression, and higher-than-expected prevalence of autoimmune thyroiditis and polycystic ovary syndrome.
Observational Study on a Large Italian Population with Lipedema: Biochemical and Hormonal Profile, Anatomical and Clinical Evaluation, Self-Reported History — Patton et al. (2024)
Major uncertainty
The true population prevalence of lipedema remains unknown. The only available estimate (~12.3% of adult women) derives from unvalidated self-report screening without clinical confirmation and is likely a substantial overestimate. All clinical cohort data come from referral centres or surgical series, introducing selection bias and precluding generalisation. The genetic basis is undetermined, and it is unclear whether the condition is genuinely underdiagnosed or whether diagnostic criteria capture a heterogeneous population. The basis for male occurrence and its true frequency also remain poorly characterised.
Version history
- SQ-LIP-000002 · v1.1 — 2026-05-31 — This update substantially expanded the epidemiological and demographic profile of lipedema by adding seven new context claims from large clinical cohorts (U.S., German, Swiss, Italian) and a scoping review, providing consistent data on age of onset, diagnostic delay, family history, reproductive milestone triggers, comorbidity burden, and quality of life impairment — none of which were present in the prior answer. · view this version
- SQ-LIP-000002 · v1.0 — 2026-05-30 — founding index (8 claims) · view this version
Key references
DOI:10.1590/1677-5449.202101981 · DOI:10.1590/1677-5449.202301832 · DOI:10.7759/cureus.87332 · DOI:10.1177/1358863x231202769 · DOI:10.1097/prs.0000000000006280 · DOI:10.3390/jpm13010098 · DOI:10.1111/dth.14534 · DOI:10.1371/journal.pone.0319099 · DOI:10.3390/ijms25031599